Alex Kesin and Matthew Pech
Approved
Life sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.
Autor
Alex Kesin and Matthew Pech
Kategorie
Podcast-Website
Neueste Folge
14. Mai 2026
Wo hören?
Podcasts in der App Replaio Radio Bald verfügbarPodcasts kommen bald in die App. Installiere sie jetzt und erlebe als Erster einen ganz neuen Blick auf Podcasts
Kostenlos installieren
Android 5 Mio.+ Downloads · Bewertung 4,8
iOS bald
Folgen
Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time 14.05.2026 2:07:36
Keytruda is Merck's $31 billion a year PD-1 inhibitor and the best-selling cancer drug of all time. In Episode 3 of Approved , Alex Kesin and Matthew Pech trace the development of pembrolizumab , featuring interviews the scientists who drove the program forward : co-inventors Gregory Carven and Michel Streuli , and former Merck oncology CMO Roy Baynes . Topics include preclinical PD1 / CTLA-4 chec...
Episode #2: Geron 13.03.2026 2:22:06
Listen on Spotify Listen on Apple Podcasts Listen on YouTube TABLE OF CONTENTS (00:00:00) - Introduction (00:01:19) - Hayflick Limit (00:08:30) - Michael West & Founding of Geron (00:15:16) - Early Science & IP Strategy (00:27:25) - Cloning the Telomerase Gene (00:29:30) - Embryonic Stem Cells & Political Context (00:44:21) - Okarma, West’s Departure & Corporate Turmoil (01:...
Episode #1: Amylin Pharmaceuticals 30.01.2026 1:46:28
Listen on Spotify Listen on Apple Podcasts Listen on YouTube TABLE OF CONTENTS (00:00:00) - Introduction (00:04:40) - $50 of Dried Lizard Venom (00:29:17) - Fax of Death (00:43:04) - Sleeping Beauty Awakens (00:52:07) - Carl Icahn Sends a Letter (01:09:19) - Endgame (01:13:40) - Postmortem & Playbook CREDITS Co-hosted by Alex Kesin and Matthew Pech Written, edited, and produced by Alex Kesin...
Ähnliche Podcasts
Höre den Podcast Approved in Replaio
Radio und Podcasts in einer App - kostenlos und ohne Anmeldung. Installiere sie noch heute und verpasse den Start nicht
Replaio ist kein Herausgeber von Podcasts; die Namen der Sendungen, Cover und Audioinhalte gehören ihren Autoren und werden über öffentliche RSS-Feeds verbreitet
